CARDIFF, United Kingdom – October 14th, 2025 – CatSci Ltd., a leading innovation partner for pharmaceutical R&D and manufacturing, today announced a strategic collaboration with BRAINBiocatalysts, part of the BRAIN Biotech Group. The partnership will accelerate the use of advanced biocatalytic solutions in drug discovery and development.
By combining CatSci’s expertise in end-to-end process research and development (PR&D) with BRAINBiocatalysts’ world-class enzyme discovery and design technologies, the two companies will deliver scalable, tailored solutions to support the development of small molecule APIs, oligonucleotides, nucleotides, RNA editing technologies, and peptides.
“This collaboration enhances CatSci’s ability to offer our customers innovative biocatalytic approaches that address some of the most complex challenges in pharmaceutical development,” said Simon Tyler, Chief Commercial Officer at CatSci. “By integrating BRAINBiocatalysts’ proprietary enzyme technologies into CatSci’s PR&D framework, we can provide a seamless path from enzyme screening through to scalable process solutions for our customers.”
A key advantage of this collaboration is the enhanced freedom to operate it provides for pharmaceutical partners. By leveraging BRAINBiocatalysts’ proprietary AI-driven enzyme discovery and enzyme engineering portfolio and CatSci’s independent PR&D capabilities, customers can confidently develop and commercialise new manufacturing routes without the burden of restrictive IP entanglements or downstream licensing obligations. Advanced strain and gene editing technologies, full fermentation, purification, and protein chromatography services ensure that novel biocatalytic processes can be scaled and implemented globally with full commercial autonomy. This freedom empowers innovators to move from concept to market with reduced legal and operational risk.
Under the agreement, CatSci will work with its customers to identify opportunities where biocatalysis can add value. By integrating BRAINBiocatalysts’ MetXtra™ platform and engineered enzyme panels into projects, CatSci will provide pharma partners with access to cutting-edge enzyme technologies, while ensuring they keep control over their development strategies.
The partnership will also open the door to joint projects in emerging therapeutic areas, advancing novel biocatalytic processes that can support the next generation of medicines.
“This agreement allows us to align our respective strengths in a way that delivers maximum benefit to the pharma industry, without disrupting existing customer relationships,” added Tyler. “It reinforces CatSci’s position as a partner of choice for pharma and biotech companies developing the next generation of medicines.”
About CatSci Ltd.
CatSci Ltd. is a leading innovation partner dedicated to delivering tailored process research and development services for pharmaceutical companies worldwide. With cutting-edge science, modern facilities, and a customer-first approach, CatSci helps bring medicines to patients faster.
About BRAINBiocatalysts
Part of the BRAIN Biotech Group, BRAINBiocatalysts Life Science Solutions offers enzyme discovery, strain development, and manufacturing expertise. With its unique IP model and full-service offering, it delivers novel, scalable biocatalysis solutions that drive innovation across the life sciences industry.
